Page 8 - Michael Strapazon News Today

Amgen To Present At The Cowen 2nd Annual Virtual Oncology Innovation Summit News provided by Share this article Share this article THOUSAND OAKS, Calif., May 19, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the Cowen 2nd Annual Virtual Oncology Innovation Summit at 11:20 a.m. ET on Friday, May 21, 2021. David M. Reese, M.D., executive vice president of Research and Development at Amgen, will present at the conference. Live audio of the conference call will be broadcast over the i...

/PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced detailed results for tezepelumab, a potential first-in-class treatment, from the pivotal...

Amgen today announced the presentation of four cardiovascular research abstracts, including final data from the Repatha ® open label extension trial of patients living with HIV who have high cholesterol, as well as new data from FOURIER evaluating biomarkers of major cardiovascular events, including complex revascularization procedures. Additional abstracts to be presented include a simulation comparing the impact … Amgen (NASDAQ:AMGN) today announced the presentation of four cardiovascular ...

Share this article Share this article THOUSAND OAKS, Calif., May 10, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced its partner AstraZeneca (NASDAQ:AZN) submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tezepelumab, a potential first-in-class medicine in severe asthma. The submission is supported by positive clinical trial results from the PATHFINDER clinical program including the pivotal NAVIGATOR Phase 3 trial, which demonstrated a...

Amgen To Present At The 2021 Bank of America Merrill Lynch Healthcare Conference News provided by Share this article Share this article THOUSAND OAKS, Calif., May 6, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2021 Bank of America Merrill Lynch Virtual Healthcare Conference at 11:00 a.m. ET on Tuesday, May 11, 2021. David M. Reese, M.D., executive vice president of Research and Development, Murdo Gordon, executive vice president of Global Commercial Operations and Peter H. Gr...

Amgen today announced that the U.S. Food and Drug Administration has accepted for review the supplemental New Drug Application for Otezla ® for the treatment of adults with mild-to-moderate plaque psoriasis who are candidates for phototherapy or systemic therapy. The FDA has set a Prescription Drug User Fee Act action date of December 19, 2021 . “Otezla has been prescribed to hundreds of thousands of patients with … – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Admin...

Amgen today announced Otezla ® improved measures of disease severity in adults with mild-to-moderate plaque psoriasis regardless of their Body Surface Area affected by the disease, according to findings from the placebo-controlled, Phase 3 ADVANCE trial. Results were presented at the American Academy of Dermatology Virtual Meeting Experience 2021. “Many people with mild-to-moderate plaque psoriasis still report … Amgen (NASDAQ:AMGN) today announced Otezla ® (apremilast) improved measures ...

Share this article THOUSAND OAKS, Calif., April 23, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced Otezla ® (apremilast) improved measures of disease severity in adults with mild-to-moderate plaque psoriasis regardless of their Body Surface Area (BSA) affected by the disease, according to findings from the placebo-controlled, Phase 3 ADVANCE trial. Results were presented at the American Academy of Dermatology Virtual Meeting Experience 2021.  "Many people with mild-to-moderate pla...

Amgen Announces Webcast Of 2021 First Quarter Financial Results News provided by Share this article Share this article THOUSAND OAKS, Calif., April 22, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Tuesday, April 27, 2021, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2:00 p.m. PT. Participating in the call from Amgen will be Robert A. B...